Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of the High Affinity Neurotensin Receptor Defines an Immune‑cold, Poor‑prognosis Colorectal Cancer Subtype.

Annals of surgery·2026
Same author

PET Imaging Characterization of Sphingosine-1-Phosphate Receptor 2 in a Mouse Model of Esophageal Adenocarcinoma and Metastatic Lymph Node.

Molecular pharmaceutics·2026
Same author

Therapeutic targeting of adhesion GPCRs: a status update and future potential.

Expert opinion on drug discovery·2026
Same author

Exploring the immune environment of glioblastoma in humanized mouse models.

Neuro-oncology·2026
Same author

Adhesion G protein-coupled receptors.

Pharmacological reviews·2026
Same author

Person-level health factors partially mediate the association between lesbian, gay, or bisexual (LGB) identity, allostatic load, and cancer mortality in NHANES.

Cancer causes & control : CCC·2026

Related Experiment Video

Updated: Jul 7, 2026

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Engineering human tumor-specific cytotoxic T cells to function in a hypoxic environment.

Hongsung Kim1, Guangyong Peng, John M Hicks

  • 1Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Methodist Hospital, Houston, Texas 77030, USA.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|January 30, 2008
PubMed
Summary

Engineered T cells can overcome tumor hypoxia, enhancing cancer immunotherapy. Modified T cells express interleukin-2 (IL-2) in low-oxygen tumors, improving T cell survival, proliferation, and anti-tumor activity for better treatment outcomes.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Related Experiment Videos

Last Updated: Jul 7, 2026

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells
09:12

Generation and Functional Verification of Hypoxia-Sensitive Chimeric Antigen Receptor-T Cells

Published on: June 14, 2024

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Area of Science:

  • Immunology
  • Oncology
  • Gene Therapy

Background:

  • Tumor hypoxia impedes cancer therapies like radio- and chemotherapy.
  • Hypoxia suppresses T lymphocyte function, cytokine production (e.g., interleukin-2), and survival.
  • This creates resistance to T cell-based immunotherapies.

Purpose of the Study:

  • To engineer T cells resistant to tumor hypoxia.
  • To enhance T cell-mediated anti-tumor immunity in hypoxic tumor microenvironments.
  • To improve the efficacy of adoptive T cell therapy for solid tumors.

Main Methods:

  • Constructed a lentiviral vector with a hypoxia-inducible responsive element (HRE) to drive interleukin-2 (IL-2) expression.
  • Transduced tumor-specific T cells with the HRE-IL-2 vector.
  • Evaluated IL-2 expression, T cell survival, proliferation, and effector function under varying oxygen tensions in vitro and in vivo using a human B cell lymphoma model.

Main Results:

  • Transduced T cells upregulated IL-2 expression in low-oxygen conditions (down to 1% O2).
  • Enhanced T cell survival, proliferation, and sustained effector function were observed in hypoxic environments.
  • HRE-IL-2 modified cytotoxic T lymphocytes (CTLs) demonstrated faster and more complete tumor regression and increased overall survival compared to parental CTLs.
  • Transduced cells maintained their phenotype and tumor-homing ability.

Conclusions:

  • Hypoxia-resistant T cells engineered with HRE-IL-2 can overcome tumor microenvironment limitations.
  • This strategy enhances T cell-mediated anti-tumor immunity and improves therapeutic outcomes.
  • Engineered T cells offer a promising approach for treating hypoxic human tumors resistant to current therapies.